ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1061

Patients with Fibromyalgia (FM) Do Not Fulfill Classification Criteria for Axial Spondyloarthritis (axSpA) but Patients with Axspa May Fulfill Classification Criteria for FM

Xenofon Baraliakos1, Andrea Regel1, Uta Kiltz1, Hans-Jürgen Menne2, Friedrich Dybowski3, Manfred Igelmann4, Ludwig Kalthoff3, Dietmar Krause5, Ertan Saracbasi1, Elmar Schmitz-Bortz6 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumatology practice, Dortmund, Germany, 3Private rheumatology office, Herne, Germany, 4Private Rheumatology office, Bochum, Germany, 5Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, 6Rheumatology practice, Hattingen, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS), Classification criteria and fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Both patients with axial spondyloarthritis (axSpA) and patients with fibromyalgia (FM) are suffering from pain. The new ASAS classification criteria for axSpA have been recently challenged by arguing that FM patients could easily fulfill the clinical arm of the criteria, which could lead to overdiagnosis of axSpA and wrong treatment decisions.  In this study we examined similarities and differences between axSpA and FM using different sets of classification criteria and to assess the severity of wide-spread pain in both diseases.

Methods: In this prospective study, patients were consecutively included if they were diagnosed with axSpA, or FM by a rheumatologist. Patients with rheumatoid arthritis (RA) were also included as an inflammatory control group. Patients on anti-TNF treatment were not included. Established classification and outcome parameters as well as standardized instruments were used in all patients. MRI performed in all axSpA and 20 FM patients. All axSpA and FM patients had radiographs. The Mann-Whitney-U test was used for statistical comparisons between groups.

Results: A total of 214 patients was included: 93 with FM (7.5% HLA B27+), 91 with axSpA (79.1% HLA-B27+) and 30 with RA (53.3% seropositive). The mean age was 50.7±9.1, 43.0±12 and 58.4±11.9 years, respectively, and the mean symptom duration was comparable between groups: 6.6±6.9, 6.4±7.8 and 6.2±11.3, respectively. Expectedly, the gender ratio differed: FM and RA patients were mostly female (93.4% and 76.7%, respectively), as compared to axSpA patients (28.3%). The ASAS classification criteria were not fulfilled by any FM patient. In contrast, the 1990 and 2010 FM criteria were fulfilled by 98.3% and 100% of patients with FM, but also by 14.3% and 34.1% of axSpA (no differences between AS and nr-axSpA) and 30% and 46.7% of RA patients, respectively. The Fibromyalgia impact questionnaire (FIQ) values were 69.5±13.0, 45.4±19.3 (p<0.001) and 49.9±22.8, respectively, while the Health Assessment Questionnaire (HAQ) values were 1.7±0.5, 1.2±0.5 (p<0.001) and 1.6±0.8, for FM, axSpA and RA, respectively. FM patients reported the highest pain scores on a 0-10 numeric rating scale: 7.0±1.7 vs. 6.0±1.9 and 6.1±1.9 in axSpA and RA patients, respectively, while mean CRP values (mg/dl) were higher in axSpA (1.1±1.3) and RA (0.6±0.9) patients vs. FM (0.4±0.4) (both p<0.001). 

Conclusion: Importantly, no FM patients fulfilled ASAS classification criteria. Only a small proportion of patients with axSpA fulfilled any of the FM classification criteria. There was less overlap between patients with FM, axSpA and RA using the 1990 criteria as compared to the more sophisticated 2010 FM criteria. FM patients reported higher pain scores and more functional deficits. Some patients with widespread pain may have underlying axSpA – this differential diagnosis needs to be taken into account when dealing with the diagnosis of FM in daily practice.


Disclosure: X. Baraliakos, None; A. Regel, None; U. Kiltz, None; H. J. Menne, None; F. Dybowski, None; M. Igelmann, None; L. Kalthoff, None; D. Krause, None; E. Saracbasi, None; E. Schmitz-Bortz, None; J. Braun, None.

To cite this abstract in AMA style:

Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbasi E, Schmitz-Bortz E, Braun J. Patients with Fibromyalgia (FM) Do Not Fulfill Classification Criteria for Axial Spondyloarthritis (axSpA) but Patients with Axspa May Fulfill Classification Criteria for FM [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/patients-with-fibromyalgia-fm-do-not-fulfill-classification-criteria-for-axial-spondyloarthritis-axspa-but-patients-with-axspa-may-fulfill-classification-criteria-for-fm/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-fibromyalgia-fm-do-not-fulfill-classification-criteria-for-axial-spondyloarthritis-axspa-but-patients-with-axspa-may-fulfill-classification-criteria-for-fm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology